Variability in the extent of del(5q) and its clinical implication in myelodysplastic syndromes (MDS).

被引：0
|
作者：
Zemanova, Zuzana
Brezinova, Jana
Svobodova, Karla
Lhotska, Halka
Izakova, Silvia
Sarova, Iveta
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e19025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19025
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Myelodysplastic syndromes (MDS) with a deletion 5q display a specific immunophenotypic profile
    Oelschlaegel, U.
    Westers, T. M.
    Mohr, B.
    Parmentier, S.
    Sockel, K.
    Bornhaeuser, M.
    Van de Loosdrecht, A. A.
    Platzbecker, U.
    LEUKEMIA RESEARCH, 2013, 37 : S47 - S48
  • [22] ROLE OF LENALIDOMIDE IN MANAGEMENT OF MYELODYSPLASTIC SYNDROMES (MDS) WITH DEL(5Q) ASSOCIATED WITH PURE RED CELL APLASIA (PRCA)
    Cerchione, C.
    Cerciello, G.
    Della Pepa, R.
    Pugliese, N.
    Marano, L.
    Vitagliano, O.
    Luciano, L.
    Alfinito, F.
    Pane, F.
    Risitano, A.
    HAEMATOLOGICA, 2013, 98 : 691 - 692
  • [23] IMPACT OF 5Q BREAKPOINTS ON CLINICAL OUTCOMES IN PATIENTS WITH IPSS LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ISOLATED DEL(5Q) TREATED WITH LENALIDOMIDE IN THE MDS-004 STUDY
    Gohring, G.
    Giagounidis, A.
    List, A.
    Hellstrom-Lindberg, E.
    Sekeres, M.
    Mufti, G.
    Schlegelbergerl, B.
    Morrill, J.
    Wu, C.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2013, 98 : 80 - 80
  • [24] Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes
    Heise, Carla
    Carter, Troy
    Schafer, Peter
    Chopra, Rajesh
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (10) : 1663 - 1672
  • [25] Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide
    Gerds, Aaron T.
    List, Alan F.
    Giagounidis, Aristoteles
    Hellstrom-Lindberg, Eva
    Li, Jack Shiansong
    Swern, Arlene S.
    Sugrue, Mary M.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [26] Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations
    Mallo, Mar
    del Rey, Monica
    Ibanez, Mariam
    Jose Calasanz, Ma
    Arenillas, Leonor
    Jose Larrayoz, Ma
    Pedro, Carmen
    Jerez, Andres
    Maciejewski, Jaroslaw
    Costa, Dolors
    Nomdedeu, Meritxell
    Diez-Campelo, Maria
    Lumbreras, Eva
    Gonzalez-Martinez, Teresa
    Marugan, Isabel
    Such, Esperanza
    Cervera, Jose
    Cigudosa, Juan C.
    Alvarez, Sara
    Florensa, Lourdes
    Hernandez, Jesus Ma
    Sole, Francesc
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (01) : 74 - 86
  • [27] Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
    Vozella, Federico
    Latagliata, Roberto
    Carmosino, Ida
    Volpicelli, Paola
    Montagna, Chiara
    Romano, Angela
    Roberto, Amanda
    Finsinger, Paola
    Mancini, Marco
    Breccia, Massimo
    Oliva, Esther
    Alimena, Giuliana
    HEMATOLOGICAL ONCOLOGY, 2015, 33 (01) : 48 - 51
  • [28] Interphase FISH Does Not Improve the Detection of DEL(5q) and DEL(20q) in Myelodysplastic Syndromes
    Douet-Guilbert, Nathalie
    Herry, Angele
    Le Bris, Marie-Josee
    Gueganic, Nadia
    Bovo, Clement
    Morel, Frederic
    De Braekeleer, Marc
    ANTICANCER RESEARCH, 2011, 31 (03) : 1007 - 1010
  • [29] MYELODYSPLASTIC SYNDROME WITH DEL(5Q) AND LENALIDOMIDE
    Gritsaev, S. V.
    Martinkevitch, I. S.
    Petrova, E. V.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2013, 58 (02): : 3 - 10
  • [30] Morphological alterations of megakaryocytes in myelodysplastic syndromes with del(5q), del(20q), -7 and del(7q)
    Avino, Daniela
    Di Palma, Anna
    Caliendo, Irene
    Soriente, Ilaria
    Di Feo, Angelo
    Danise, Paolo
    BIOCHIMICA CLINICA, 2016, 40 (03) : 229 - 233
12345